FDA Approves Jardiance to Reduce Cardiovascular Death
The US Food and Drug Administration (FDA) has approved a new indication for Jardiance (empagliflozin) to reduce the risk of cardiovascular death in adult patients with type 2 diabetes mellitus and cardiovascular disease. ‘Cardiovascular disease is a leading cause of death in adults with type 2 diabetes mellitus,’ said Jean-Marc Guettier, MD, CM, Director of [...]